Permeability of the blood-brain barrier for protein fractions 50-100 kDa (PF) of Cellex Daily preparation labeled with fluorescent tracer FITC and non-conjugated FITC were compared after intranasal administration of the preparations to healthy rats. Fluorimetrical analysis of the serum and cerebrospinal fluid samples showed that Cellex Daily PF-FITC administered intranasally penetrated into the blood and cerebrospinal fluid with maximum accumulation in 2 h after administration and persists in the circulation for 24 h probably due to binding with plasma proteins. The differences in the kinetic profile of PF-FITC and free FITC indirectly suggest that the major part of the preparation is not degraded within 24 h and FITC is probably not cleaved from the protein components of the preparation. In vivo fluorescence analysis showed significant fluorescent signal in the olfactory bulbs in 6 h after intranasal administration; hence, the preparation administered via this route can bypass the blood-brain barrier. Scanning laser confocal microscopy of rat brain sections confirmed penetration of the high-molecular weight protein fraction PF-FITC into CNS structures. The most pronounced accumulation of the labeled drug was observed in the olfactory bulb in 6 and 12 h after administration. In contrast to free FITC administered in the control group, significant accumulation of PF-FITC in the olfactory cortex and frontal cortex neurons with functionally active nuclei was observed in 6, 12 and 24 h after intranasal administration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10517-017-3974-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer.
Cancer Treat Rev
January 2025
Department of Medicine I, Division of Oncology, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. Electronic address:
Article Synopsis
- - Patients with HER2-positive breast cancer face a high risk of brain metastases, impacting their survival and quality of life, and there is a need for better primary prevention strategies.
- - Experts developed consensus statements through a modified Delphi process to address current unmet needs and assess available evidence on brain metastases management.
- - Out of 55 statements reviewed by contributors, 34 achieved consensus regarding areas like prevention, screening, and treatment efficacy, while some statements lacked agreement due to insufficient evidence; these consensus statements can guide clinical practice and future research.
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial.
JTO Clin Res Rep
July 2024
Tennessee Oncology, Nashville, Tennessee.
Article Synopsis
- The JAVELIN Lung 101 trial tested avelumab, an immune checkpoint inhibitor, alongside lorlatinib or crizotinib (tyrosine kinase inhibitors) in advanced non-small cell lung cancer (NSCLC).
- The study aimed to determine the maximum tolerated dose (MTD) and evaluate the treatment's effectiveness based on patient response rates, focusing on dose-limiting toxicities (DLTs).
- Results showed that avelumab with lorlatinib was manageable with a response rate of 52%, while avelumab with crizotinib was less feasible, with a lower response rate of 25% and high DLT incidence.
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.
Lancet Haematol
May 2024
University Hospital TU Dresden, Dresden, Germany; DKMS gemeinnützige GmbH, Tübingen und Dresden, Germany. Electronic address:
Article Synopsis
- The study investigates if high-dose cytarabine-based salvage chemotherapy before allogeneic stem-cell transplantation improves survival in patients with acute myeloid leukaemia who haven't responded well to previous treatments.
- 281 patients aged 18 to 75 were randomly assigned to either receive chemotherapy or immediate stem-cell transplantation; the main goal was to measure treatment success as complete remission by day 56 after HSCT.
- Results showed that 83% of patients in the chemotherapy group achieved treatment success, suggesting that prior chemotherapy could be an effective approach before transplantation in these patients.
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8.
Breast
December 2023
Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. Electronic address:
Background: Preclinical data suggest synergistic activity with the combination of programmed death-1 and cyclin-dependent kinase 4/6 blockade in oestrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer. The noncomparative phase 1b/2 CheckMate 7A8 study (NCT04075604) evaluated neoadjuvant treatment with nivolumab, palbociclib, and anastrozole in patients with ER+/HER2- breast cancer. Here, we report outcomes from the safety run-in phase.
View Article and Find Full Text PDF[Neurological aspects of diagnosis and treatment of motor alalia].
Zh Nevrol Psikhiatr Im S S Korsakova
June 2023
Omsk State Medical University, Omsk, Russia.
Objective: To analyze the causes of violations of expressive speech in children 4-5 years old, to assess changes in neurological status in children with motor alalia without and during treatment with Cellex.
Material And Methods: Two groups of patients were recruited: the main group (=30; treatment; Cellex) and the control group (=12; without Cellex). The drug was administered in the first half of the day by 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!